Table 1.
Clinical characteristics, grouped by AFP response (AFP reduction by ⩾20%).
| Characteristic | Not evaluable (n = 51) | AFP non-responder (n = 66) | AFP responder (n = 58) | p Value |
|---|---|---|---|---|
| Male | 45 (88.2) | 59 (89.4) | 50 (86.2) | 0.860 |
| Ethnicity | 0.986 | |||
| White | 32 (62.7) | 36 (54.5) | 41 (70.7) | |
| Asian | 13 (25.5) | 24 (36.4) | 8 (13.8) | |
| Black | 3 (5.9) | 6 (9.1) | 6 (10.3) | |
| Latinx | 1 (2.0) | 0 (0.0) | 1 (1.7) | |
| American Indian or Alaska Native | 2 (3.9) | 0 (0.0) | 2 (3.4) | |
| Viral status | ||||
| Active/prior HBV infection | 27 (52.9) | 33 (50.0) | 21 (36.2) | 0.262 |
| Active/prior HCV infection | 25 (49.0) | 32 (48.5) | 26 (44.8) | 0.769 |
| Non-viral | 17 (33.3) | 19 (28.8) | 22 (37.9) | 0.369 |
| Child-Pugh class | 0.248 | |||
| A | 43 (86.0) | 55 (83.3) | 54 (93.1) | |
| B | 7 (14.0) | 11 (16.7) | 4 (6.9) | |
| BCLC stage | 0.370 | |||
| A | 1 (2.0) | 1 (1.5) | 2 (3.4) | |
| B | 8 (15.7) | 4 (6.1) | 4 (6.9) | |
| C | 42 (82.4) | 61 (92.4) | 52 (89.7) | |
| Baseline AFP | 6 [4, 13] | 1084 [131, 9187] | 29357 [99, 6237] | <0.001 |
| Best AFP change within 3 months (using lowest available on-treatment AFP value) | N/A | +39.1% [+10.5%, +110.1%] | −66.9% [−51.4%, −85.2%] | <0.001 |
| SOR monotherapy | 25 (49.0) | 29 (43.9) | 33 (56.9) | 0.352 |
| Other drug | 0.325 | |||
| Chemotherapy | 7 (13.7) | 11 (16.7) | 10 (17.2) | |
| Targeted therapy | 17 (33.3) | 16 (24.2) | 23 (39.7) | |
| SOR discontinued | 50 (98.0) | 64 (97.0) | 56 (96.6) | 0.892 |
| Immunotherapy after SOR | 14 (27.5) | 15 (22.7) | 17 (29.3) | 0.690 |
| Death | 46 (90.2) | 53 (80.3) | 37 (63.8) | 0.003 |
Data are median (IQR) or n (%).
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B; HCV, hepatitis C; IQR, interquartile range; SOR, sorafenib.